Evidence map›Paper›PMID 28752230›Full record

ReviewRheumatology international2018

Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review.

Jurgen Sota, Donato Rigante, Giuseppe Lopalco, Bruno Frediani, Rossella Franceschini, Mauro Galeazzi, Florenzo Iannone, Gian Marco Tosi, Claudia Fabiani, Luca Cantarini

Abstract readReview
PubMed Publisher
In one paragraph

Review in Rheumatology international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Behçet's Disease Uveitis.Journal of clinical medicine · 2023
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Behçet's Disease in Children: Diagnostic and Management Challenges.Therapeutics and clinical risk management · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Jurgen SotaRheumatology Unit, Policlinico "Le Scotte", Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases, Behçet's Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, University of Siena, viale Bracci 1, 53100, Siena, Italy.
Donato RiganteInstitute of Pediatrics, Periodic Fever Research Center, Università Cattolica Sacro Cuore, Fondazione Policlinico A. Gemelli, Rome, Italy.
Giuseppe LopalcoRheumatology Unit, Interdisciplinary Department of Medicine, University of Bari, Bari, Italy.
Bruno FredianiRheumatology Unit, Policlinico "Le Scotte", Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases, Behçet's Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, University of Siena, viale Bracci 1, 53100, Siena, Italy.
Rossella FranceschiniOphthalmology and Neurosurgery Department, University of Siena, Siena, Italy.
Mauro GaleazziRheumatology Unit, Policlinico "Le Scotte", Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases, Behçet's Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, University of Siena, viale Bracci 1, 53100, Siena, Italy.
Florenzo IannoneOphthalmology and Neurosurgery Department, University of Siena, Siena, Italy.
Gian Marco TosiOphthalmology and Neurosurgery Department, University of Siena, Siena, Italy.
Claudia FabianiDepartment of Ophthalmology, Humanitas Research Hospital, Rozzano, Milan, Italy.
Luca CantariniRheumatology Unit, Policlinico "Le Scotte", Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases, Behçet's Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, University of Siena, viale Bracci 1, 53100, Siena, Italy. cantariniluca@hotmail.com.ORCID http://orcid.org/0000-0002-7352-1275
University of Siena · ITIRCCS Humanitas Research Hospital · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intraocular inflammation is one of the more relevant complications of Behçet's disease (BD), which tends to respond poorly to different medications. The ocular histopathologic changes are basically identical to those occurring in other organs and consist in a necrotizing leukocytoclastic obliterative vasculitis, which is probably immune complex-mediated and affects both arteries and veins of all sizes. There are growing evidences showing the potential role of biologic agents other than anti-tumor necrosis factor (TNF)-α agents in the management of ocular-BD, which have been collected in this review, including interleukin-1 and interleukin-6 blockade, secukinumab, ustekinumab, daclizumab, rituximab, and alemtuzumab. Further large studies are needed to fully elucidate and establish the clinical efficacy of these different tools in the refractory ocular manifestations of BD.

Indexed as

Interleukin-6 InhibitorsBehcet SyndromeBiological ProductsHumansInterleukin-1Treatment OutcomeUveitisBiological ProductsInterleukin-1Interleukin-6 InhibitorsBehçet’s diseaseBiologicsEye diseaseTreatmentUveitis

Identifiers

PMID28752230
OpenAlexW2740799220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.